Search Results

China's Qinshan Nuclear Power Expands Isotope Production and Medical Application Industry Chain

Recently, the commercial heavy water reactors at Qinshan Nuclear Power have been producing isotopes such as cobalt-60, carbon-14, lutetium-177, and yttrium-90 while continuing to supply electricity, expanding the comprehensive utilization pathways of nuclear power units. Qinshan possesses the only two commercial heavy water reactor units in China, with an annual power generation of approximately 12 billion kWh, and their reactor irradiation capability also provides production conditions for isotope preparation. Isotope production utilizes neutrons within the reactor to irradiate specially designed targets, forming target nuclides through nuclear reactions and subsequent decay. Different nuclides require different target materials, irradiation conditions, and processing procedures. After irradiation is completed, targets must undergo corresponding processing and quality inspection before entering subsequent product manufacturing...

2026-11-07

China's domestically developed new-generation medical heavy-ion accelerator demonstration facility completed in Huizhou

Recently, the Institute of Modern Physics of the Chinese Academy of Sciences announced that the first demonstration facility of China's domestically developed new-generation medical heavy-ion accelerator—the ultra-compact rotating beam heavy-ion therapy system—has been officially completed at the Huizhou Heavy Ion Medical Center in Guangdong Province. It is understood that the facility integrates multiple transformative technologies, including a novel disc-structured milliampere-level high-intensity linear injector, an ultra-short-circumference high-repetition-rate synchrotron, and a high-performance intelligent rotating beam delivery system. It covers an area of only 1,200 square meters and is expected to have an annual treatment capacity of 2,000 to 5,000 cases. While significantly reducing construction and operation and maintenance costs, it will further lower patients' medical expenses and comprehensively help high-end medical equipment achieve universal accessibility...

2026-10-28

Southwest Supervision Station of the National Nuclear Safety Administration Conducts Demonstrative Supervision of Radiopharmaceuticals

Recently, the Southwest Nuclear and Radiation Safety Supervision Station of the Ministry of Ecology and Environment (National Nuclear Safety Administration), together with the Department of Radiation Source Safety Supervision, the Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment, and Chengdu University of Technology, organized representatives of enterprises in its jurisdiction to conduct demonstrative supervision of radiopharmaceutical (medical isotope) production. This initiative aims to serve the national "Medium- and Long-Term Development Plan for Medical Isotopes (2021–2035)" and comprehensively enhance the radiation safety management level of the nuclear medical industry in the Southwest region. It is reported that this supervision activity practiced the concept of research-based supervision. In response to the characteristics of the Southwest region—where R&D, pilot testing, and large-scale production proceed in parallel, and the safety risks of unsealed radioactive materials are complex—the activity involved pre-arranging production processes...

2026-10-22

Oklo Advances Construction of Groves-2 Forge Isotope Pilot Facility, Deepening Medical and Industrial Isotope Layout

Recently, U.S. nuclear technology startup Oklo announced that it will further advance the construction of the Groves-2 Forge isotope production and processing pilot facility. Located in Texas, the facility aims to build on the successful demonstration experience of the company's previous Groves Isotope Testing Reactor to comprehensively expand irradiation, processing, purification, and commercialization readiness capabilities for key isotopes. It is understood that the Groves-2 Forge facility will integrate cutting-edge hot cell processing capabilities, covering the full process chain including isotope separation, product recovery, packaging, and transportation. The facility's initial production focus will be on lutetium-177 (Lutetium-177) used for cancer radiopharmaceutical therapy and other important therapeutic isotopes...

2026-10-15

China's First Actinium-225 Mass Production Qualification Lands in Chongqing: SPIC Isotope Synergy Accelerates Breakthrough in High-End Medical Isotope Supply Chain Bottleneck

The Ministry of Ecology and Environment recently officially issued a Class A unsealed radioactive material radiation safety license to SPIC Isotope Synergy (Chongqing) Technology Co., Ltd. The issuance of this administrative license marks that the company has officially become the first enterprise in China with full-chain legal qualifications for the mass production, sales, and use of the medical isotope Actinium-225 (Ac-225), filling the gap in China's large-scale supply of novel targeted radionuclides. SPIC Isotope Synergy is located in Bafu Town, Chongqing High-tech Zone, and has been selected for the 2026 Chongqing Potential Unicorn Enterprise Cultivation List. The first phase of the project has a total investment of 918 million RMB, with core technical equipment relying on self-built 120 MeV and 50 MeV high-power medical proton cyclotrons.

2026-10-15

Iran Signs Memorandum on Nuclear Technology for Medical Applications to Control Dengue Fever Through Radiation-Sterilized Mosquitoes

Recently, the Iranian Ministry of Health and the Atomic Energy Organization of Iran (AEOI) signed a memorandum of understanding to expand the application of nuclear technology in the healthcare sector. Iranian Health Minister Mohammad-Reza Zafarqandi and AEOI Chairman Mohammad Eslami signed the agreement, with the primary goal of controlling the Aedes mosquito population through the sterile insect technique (SIT) to combat dengue fever, chikungunya, and Zika virus. It is understood that SIT is an environmentally friendly pest control method: male mosquitoes are mass-reared, sterilized using radiation, and then released to significantly reduce mosquito populations. Both parties will utilize Iran's scientific, research, and technological capabilities to establish a mass-rearing center for Aedes aegyp...

2026-10-13

The 18th National Symposium on Radiopharmaceuticals and Labeled Compounds Held in Chongqing, Focusing on Alpha Nuclide Targeting and Theranostics

The 18th National Symposium on Radiopharmaceuticals and Labeled Compounds was held on October 10-11 at the Chongqing Science Hall. The conference was co-hosted by the China Isotope & Radiation Corporation Research Institute and the IAEA Collaborating Centre for Radiopharmaceuticals and Radioactive Sources, co-organized by the Nuclear Medicine Branch of the Chinese Medical Association, the Isotope Branch of the Chinese Nuclear Society, the Radiopharmaceuticals Branch of the Chinese Nuclear Society, and the Nuclear Chemistry and Radiochemistry Branch of the Chinese Nuclear Society, and undertaken by China Isotope & Radiation Corporation and the Chongqing Nuclear Society. More than 400 experts, scholars, clinicians and...

2026-10-12

CNNC Headway's Self-Developed 50mg Urea [¹³C] Powder Sachet Kit Approved, Establishing an Independent "Dual Dosage Form, Dual Specification" Landscape for Carbon-13 Breath Diagnosis

On October 8, 2026, the 50mg urea [¹³C] powder sachet breath test kit independently developed by Shenzhen CNNC Headway Biotechnology Co., Ltd. (CNNC Headway), a subsidiary of China Isotope & Radiation Corporation under CNNC, officially obtained the drug registration certificate issued by the National Medical Products Administration. This product is not only the first generic drug of the same variety approved for marketing in China in the 9 years since the implementation of the new drug review and approval regulations in 2017, but also another key achievement of CNNC Headway following the 75mg urea [¹³C] breath test kit becoming the first to pass the generic drug consistency evaluation, marking that China has officially formed a capsule + powder dual dosage form and 75mg + 50mg dual specification independent supply matrix in the field of Helicobacter pylori (Hp) breath testing...

2026-10-11

Radiology Institute Joins Hands with Peking Union Medical College Hospital and Tianyi Keyuan to Win Gold at National Invention Exhibition: Novel Medical Radiation Protection Materials Achieve Scaled Translational Application

At the recently held 30th National Invention Exhibition · Belt and Road & BRICS Skills Development and Technology Innovation Competition, the project "Key Technologies for Brachytherapy Radiation Protection Materials and Series of Radiation Protection Products," jointly applied for by the Institute of Radiation Medicine, Chinese Academy of Medical Sciences (Radiology Institute), Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (Peking Union Medical College Hospital), and Tianjin Tianyi Keyuan Technology Co., Ltd. (Tianyi Keyuan), stood out from numerous competing projects and won the Gold Award by virtue of key technological breakthroughs in the field of medical radiation protection. The award-winning project focuses on the long-standing radiation protection pain points in the clinical frontline of interventional therapy and brachytherapy. Through cross-disciplinary collaborative research by the three parties of medicine, research, and enterprise, it has systematically developed a series of innovative product matrices covering scenarios such as occupational health protection for medical staff, protection of normal tissues during radiotherapy for tumor patients, and specialized protection for scar radiotherapy.

2026-10-09

Civil Construction of Huizhou Heavy Ion Medical Center Passes Completion Acceptance and Transitions to Accelerator No-Load Commissioning

Recently, according to public information from the Huizhou Municipal Health Bureau, all approval procedures for the Heavy Ion Medical Center project of Huizhou Municipal Central Hospital have been completed, civil construction is 99.6% complete and has passed completion acceptance, and internal decoration and accelerator no-load commissioning are currently underway; the accelerator equipment investment is 480 million yuan, of which 303 million yuan has been disbursed. The project is planned to launch clinical trials in March 2027 and be officially put into operation by the end of the year. The center is adjacent to the Jinshan Campus of Huizhou Municipal Central Hospital, with a land area of approximately 12,000 square meters and a total floor area of 15,450 square meters; all heavy ion treatment rooms are located underground; 150 supporting inpatient beds are planned, with 2 treatment rooms to be opened initially, capable of treating approximately 900 cancer patients per year. The center...

2026-09-30

Rosatom RDS presented domestic high-end medical equipment in Perm to accelerate regional healthcare import substitution

On September 25, 2026, the Second International Conference "Bioethics – A Panoramic View of the Future" (Биоэтика – панорамный взгляд в будущее) successfully concluded in Perm, Russia. Rosatom RDS JSC (АО «Росатом РДС»), the industry integration platform under the Russian State Atomic Energy Corporation (Rosatom) responsible for instruments and electronic equipment manufacturing, participated deeply in this event. During the special seminar on "Ethical Considerations of the Peaceful Use of Atomic Energy in Medicine" held as part of the conference, Rosatom RDS representatives...

2026-09-27

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Promotes the Translation and Application of Medical X-ray Skin Protective Agent

On September 10, Zhang Jianhong, Party Secretary of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, led a delegation to Nanjing to conduct research with the Institute of Dermatology, Chinese Academy of Medical Sciences and Jiangsu Haizhi Biomedical Co., Ltd., exchanging views on the translation and application of the medical X-ray skin protective agent project. Representatives from the hospital, research institute, and enterprise held discussions on industry-university-research collaboration, clinical demand alignment, and industrialization pathways. It is understood that the medical X-ray skin protective agent is one of the core products in the radiation protection series independently developed by the Institute of Radiation Medicine. After being put into production, the product is expected to become China's first medical X-ray skin protective agent for scar radiotherapy. At the symposium, Zhang Jianhong stated that dermatology...

2026-09-12

Denmark's Region East Denmark to expand Sectra One imaging platform, unifying regional nuclear medicine and other medical imaging services

Swedish medical imaging IT and cybersecurity company Sectra has recently signed a contract to expand the application of its Sectra One enterprise imaging solution from hospitals in Denmark's Capital Region to the entire Region East Denmark. Region East Denmark was formed by merging the Capital Region and Region Zealand, and this expansion aims to promote unified operation of imaging services across hospitals in the entire region. Under the contract, Sectra One will be delivered as a fully managed cloud service, covering all hospitals in Region East Denmark for the review and storage of radiology medical images, including breast imaging, nuclear medicine, and clinical physiology. Hospitals in Region Zealand will migrate to the system currently in use in the Capital Region,...

2026-09-11

Canada Supports IAEA "Rays of Hope" Initiative for the First Time, Will Provide Medical Isotope Training for Latin America

The Canadian Nuclear Isotope Council (CNIC) announced on September 10 that Canada has for the first time formally provided support to the International Atomic Energy Agency (IAEA) Rays of Hope initiative, and will help enhance cancer diagnosis and treatment capacity in Latin America through training in the production of medical radioisotopes and radiopharmaceuticals. The Rays of Hope initiative aims to expand access to cancer treatment and radiotherapy infrastructure in low- and middle-income countries. Under the arrangement, from November 8 to 14, 26 relevant sector leaders from Argentina, Brazil, Chile and Mexico will travel to Ontario, Canada, to participate in a training program jointly organized by Bruce Power and McMaster University. The training will focus on medical isotopes...

2026-09-11

US Study Says Third Course of Radiation Therapy May Improve Survival and Symptoms in Children with Recurrent DIPG

According to news from the Icahn School of Medicine at Mount Sinai in the United States on September 2, researchers at the institution released a new study on re-irradiation for recurrent diffuse intrinsic pontine glioma (DIPG). The study shows that carefully selected pediatric patients who receive a third course of radiation therapy after disease recurrence may achieve symptom relief, improved quality of life, and potentially prolonged survival. The related study has been published in Practical Radiation Oncology. DIPG is a highly aggressive pediatric brain tumor that occurs in the brainstem region. The brainstem controls critical life functions such as breathing and movement, so the tumor usually cannot be removed surgically. Data show that DIPG mainly affects children aged 5 to 10, and even...

2026-09-10